NYSEAMERICAN:CVM - CEL-SCI Stock Price, News & Analysis

$8.63
-0.49 (-5.37 %)
(As of 09/18/2019 05:03 AM ET)
Today's Range
$8.32
Now: $8.63
$9.64
50-Day Range N/A
52-Week Range
$2.37
Now: $8.63
$9.64
Volume1.96 million shs
Average Volume712,784 shs
Market Capitalization$300.37 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and other diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of primary head and neck cancer. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza in hospitalized patients; and CEL-2000 and CEL-4000 vaccine product candidates for the treatment of rheumatoid arthritis. CEL-SCI Corporation was founded in 1983 and is headquartered in Vienna, Virginia.

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:CVM
CUSIPN/A
Phone+1-703-5069460

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$300.37 million
Next Earnings Date12/19/2019 (Estimated)
OptionableOptionable

Receive CVM News and Ratings via Email

Sign-up to receive the latest news and ratings for CVM and its competitors with MarketBeat's FREE daily newsletter.


CEL-SCI (NYSEAMERICAN:CVM) Frequently Asked Questions

What is CEL-SCI's stock symbol?

CEL-SCI trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CVM."

How were CEL-SCI's earnings last quarter?

CEL-SCI Co. (NYSEAMERICAN:CVM) announced its quarterly earnings data on Wednesday, August, 14th. The company reported ($0.37) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.10) by $0.27. The company earned $0.11 million during the quarter, compared to analysts' expectations of $0.10 million. View CEL-SCI's Earnings History.

When is CEL-SCI's next earnings date?

CEL-SCI is scheduled to release their next quarterly earnings announcement on Thursday, December 19th 2019. View Earnings Estimates for CEL-SCI.

Has CEL-SCI been receiving favorable news coverage?

Media headlines about CVM stock have trended negative on Wednesday, InfoTrie reports. The research firm identifies positive and negative news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. CEL-SCI earned a media sentiment score of -2.9 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the near future. View News Stories for CEL-SCI.

Who are some of CEL-SCI's key competitors?

What other stocks do shareholders of CEL-SCI own?

Who are CEL-SCI's key executives?

CEL-SCI's management team includes the folowing people:
  • Mr. Geert R. Kersten, CEO, Principal Accounting & Financial Officer, Treasurer and Director (Age 60)
  • Ms. Patricia B. Prichep, Sr. VP of Operations & Corp. Sec. (Age 68)
  • Dr. Eyal Talor, Chief Scientific Officer (Age 63)
  • Dr. Daniel H. Zimmerman, Sr. VP of Research & Cellular Immunology (Age 78)
  • Mr. John Cipriano, Sr. VP of Regulatory Affairs (Age 77)

Who are CEL-SCI's major shareholders?

CEL-SCI's stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (5.38%), Vanguard Group Inc. (3.95%), D.A. Davidson & CO. (1.54%), Thoroughbred Financial Services LLC (0.51%), Commonwealth Equity Services LLC (0.41%) and Northern Trust Corp (0.23%). Company insiders that own CEL-SCI stock include Daniel H Zimmerman, Eyal Talor, John Cipriano, Peter R Young and Vicente Benjamin Asuncion. View Institutional Ownership Trends for CEL-SCI.

Which institutional investors are buying CEL-SCI stock?

CVM stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc., Thoroughbred Financial Services LLC, D.A. Davidson & CO., Charles Schwab Investment Management Inc., Northern Trust Corp, Bank of New York Mellon Corp and Commonwealth Equity Services LLC. View Insider Buying and Selling for CEL-SCI.

How do I buy shares of CEL-SCI?

Shares of CVM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is CEL-SCI's stock price today?

One share of CVM stock can currently be purchased for approximately $8.63.

How big of a company is CEL-SCI?

CEL-SCI has a market capitalization of $300.37 million. View Additional Information About CEL-SCI.

What is CEL-SCI's official website?

The official website for CEL-SCI is http://www.cel-sci.com/.

How can I contact CEL-SCI?

CEL-SCI's mailing address is 8229 Boone Blvd Ste 802, VIENNA, VA 22182-2634, United States. The company can be reached via phone at +1-703-5069460.


MarketBeat Community Rating for CEL-SCI (NYSEAMERICAN CVM)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  104 (Vote Outperform)
Underperform Votes:  155 (Vote Underperform)
Total Votes:  259
MarketBeat's community ratings are surveys of what our community members think about CEL-SCI and other stocks. Vote "Outperform" if you believe CVM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CVM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel